[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR018191A1 - USE OF GLUCOCORTICOSTEROIDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASES - Google Patents

USE OF GLUCOCORTICOSTEROIDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASES

Info

Publication number
AR018191A1
AR018191A1 ARP990101816A ARP990101816A AR018191A1 AR 018191 A1 AR018191 A1 AR 018191A1 AR P990101816 A ARP990101816 A AR P990101816A AR P990101816 A ARP990101816 A AR P990101816A AR 018191 A1 AR018191 A1 AR 018191A1
Authority
AR
Argentina
Prior art keywords
manufacture
obstructive pulmonary
copd
chronic obstructive
pulmonary diseases
Prior art date
Application number
ARP990101816A
Other languages
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR018191A1 publication Critical patent/AR018191A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de glucocorticosteroide para la manufactura de un medicamento para tratar enfermedades pulmonares cronicas obstructivas (COPD) en pacientes que tienenun valor de volumen de expiracion forzada en 1 segundo (FEV1.0) > 65% del valor pronosticado y <10% de reversibilidad en ensayos de broncodilatacion. Laenfermedad pulmonar obstructiva cronica (COPD) es un enfermedad comun en los países industrializados (aproximadamente 6% de los hombres y 4% de las mujeres demás de 45 anos en el reino Unido están afectados) y es responsable de una considerable morbilidad y mortalidad. La mayoría de los pacientes son fumadores. Losdos trastornos más importantes que están asociados con COPD son la bronquitis cronica y la enfísema. Se proveen compuestos apropiados para la manufactura de unmedicamento para el tratamiento de COPD livianas/precoces, incluyendo la atenuacion de la declinacion de la funcion pulmonar.Use of glucocorticosteroid for the manufacture of a drug to treat chronic obstructive pulmonary diseases (COPD) in patients who have a forced expiration volume value in 1 second (FEV1.0)> 65% of the predicted value and <10% reversibility in trials of bronchodilation. Chronic obstructive pulmonary disease (COPD) is a common disease in industrialized countries (approximately 6% of men and 4% of women over 45 in the UK are affected) and is responsible for considerable morbidity and mortality. Most patients are smokers. The two most important disorders that are associated with COPD are chronic bronchitis and emphysema. Appropriate compounds are provided for the manufacture of a medicament for the treatment of light / early COPD, including attenuation of the decline in lung function.

ARP990101816A 1998-04-20 1999-04-20 USE OF GLUCOCORTICOSTEROIDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASES AR018191A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9801368A SE9801368D0 (en) 1998-04-20 1998-04-20 New use

Publications (1)

Publication Number Publication Date
AR018191A1 true AR018191A1 (en) 2001-10-31

Family

ID=20411015

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101816A AR018191A1 (en) 1998-04-20 1999-04-20 USE OF GLUCOCORTICOSTEROIDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASES

Country Status (10)

Country Link
EP (1) EP1073441A1 (en)
JP (1) JP2002512193A (en)
CN (1) CN1306429A (en)
AR (1) AR018191A1 (en)
AU (1) AU3062599A (en)
BR (1) BR9909786A (en)
CA (1) CA2329008A1 (en)
HK (1) HK1038703A1 (en)
SE (1) SE9801368D0 (en)
WO (1) WO1999053926A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9912534D0 (en) 1999-05-29 1999-07-28 Glaxo Group Res Ltd Novel prognostic surrogate
AR029189A1 (en) * 1999-11-02 2003-06-18 Smithkline Beecham Corp USE OF A PHOSPHODIESTERASE 4 INHIBITOR AND AN ANTI-INFLAMMATORY CORTICOESTEROID IN COMBINED FORM, SEPARATELY OR SEPARATELY SEQUENTIALLY FOR THE PREPARATION OF A MEDICINAL PRODUCT
RS51707B (en) 2002-12-12 2011-10-31 Nycomed Gmbh. Combination medicament
WO2004070058A1 (en) * 2003-02-03 2004-08-19 Bayer Healthcare Ag Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of copd
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
JP5618452B2 (en) 2003-09-16 2014-11-05 タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツングＴａｋｅｄａ ＧｍｂＨ Use of ciclesonide for the treatment of respiratory diseases
WO2005030220A1 (en) * 2003-09-26 2005-04-07 Schering Corporation Pulmonary disease treatment
CA2563556C (en) * 2004-04-20 2013-01-29 Altana Pharma Ag Use of ciclesonide for the treatment of respiratory diseases in a smoking patient

Also Published As

Publication number Publication date
JP2002512193A (en) 2002-04-23
CA2329008A1 (en) 1999-10-28
AU3062599A (en) 1999-11-08
BR9909786A (en) 2000-12-19
HK1038703A1 (en) 2002-03-28
EP1073441A1 (en) 2001-02-07
WO1999053926A1 (en) 1999-10-28
SE9801368D0 (en) 1998-04-20
CN1306429A (en) 2001-08-01

Similar Documents

Publication Publication Date Title
Pavithra Eugenol-a review
Kaiser et al. Systemic hypotension: a risk factor for glaucomatous damage?
AR018191A1 (en) USE OF GLUCOCORTICOSTEROIDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASES
AR013506A1 (en) USE OF A PHARMACEUTICAL COMPOSITION FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO BE USED IN THE TREATMENT OF DISEASES OF PULMONARCHRONIC OBSTRUCTION AND OF A KIT INCLUDING FORMOTEROL OR A SALT OR SOLVATE OF THE SAME AND BUDESONIDE
ES2093735T3 (en) MELATONIN DERIVATIVES FOR USE IN SLEEP DISORDERS THERAPY AND IN PRE-ANESTHETIC MEDICATION.
YU106192A (en) NEW COMBINATION OF BRONHODILATOR AND STEROID ANTI-INFLAMMATORY MEDICINE FOR TREATMENT OF RESPIRATORY DISORDERS
Capasso et al. Reduction of agonist‐induced contractions of guinea‐pig isolated ileum by flavonoids
AR018717A1 (en) COMPOUNDS DERIVED FROM PIPERIDINE, ITS USE, A PROCESS FOR ITS PREPARATION, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM, AND INTERMEDIARY COMPOUNDS.
US5569679A (en) Pharmacologic management of snoring
CR6834A (en) COMPLEXES AND COMPOSITIONS OF MACROMOLECULAR DRUGS CONTAINING THE SAME
ES2153906T3 (en) USE OF INCENSE FOR THE TREATMENT OF ALZHEIMER&#39;S DISEASE.
Verma et al. Evaluation of analgesic activity of Syzygium aromaticum w. sr to painful tooth
MX9205568A (en) PHARMACEUTICAL COMPOSITION CONTAINING AMOUNTS OF 5-AMINO-1BETA-D-RIBOFURANOSIL-IMIDAZOLE-4-CARBOXAMIDE.
AR023687A1 (en) A COMPOSITION FOR THE TREATMENT OF EXTERNAL RETINA DISORDERS AND THE USE OF A GLUTAMATE ANTAGONIST FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF EXTERNAL RETINA DISORDERS
US6440391B1 (en) Management of snoring by oral administration of dimethyl sulfone
CO4940448A1 (en) GLASS MODIFICATION OF A MEDICINAL SUBSTANCE
Grover et al. Curcumin: A medicinal plant and its effects in medicine and dentistry
Perić et al. Efficacy and safety of combined treatment of acute rhinosinusitis by herbal medicinal product Sinupret and mometasone furoate nasal spray
ES2086536T3 (en) USE OF KETOROLACO FOR THE TREATMENT OF PERIODONTAL DISEASE.
AR123872A1 (en) ORALLY DISINTEGRATING TABLET, PREPARATION PROCEDURE THEREOF, PROCEDURE TO PREVENT OR TREAT DISEASES AND USE THEREOF
AR042152A1 (en) USE OF 2,5 DIHYDROXIBENCESULPHONIC COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR DIABETIC PATIENTS
Stivelman Atelectasis in pulmonary tuberculosis
RU2141816C1 (en) Visposil agent for treatment of parodontium and traumata of muscous membrane of the oral cavity
Thakur et al. Management of Ekakushta, with special reference to psoriasis, through Panchakarma: A case study
Robo et al. Marijuana usage, the effects in oral health

Legal Events

Date Code Title Description
FB Suspension of granting procedure